Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). (Q46774150)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

alpha-1-antitrypsin deficiency

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Michael A. Campos

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Charlie Strange

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Friedrich Kueppers

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

James M Stocks

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Junliang Chen

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Rhonda Griffin

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Laurene Wang-Smith

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Mark L Brantly

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

0 references

publication date

17 July 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

COPD: Journal of Chronic Obstructive Pulmonary Disease

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

687-695

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

A review of augmentation therapy for alpha-1 antitrypsin deficiency

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group.

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy.

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Replacement therapy for hereditary alpha1-antitrypsin deficiency. A program for long-term administration

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

1 reference

https://api.crossref.org/works/10.3109%2F15412555.2013.800852

21 January 2018

Identifiers

10.3109/15412555.2013.800852

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23862647%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46774150&oldid=2143785510"